These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 28742500)

  • 41. The cardiovascular risk of gonadotropin releasing hormone agonists in men with prostate cancer: an unresolved controversy.
    Conteduca V; Di Lorenzo G; Tartarone A; Aieta M
    Crit Rev Oncol Hematol; 2013 Apr; 86(1):42-51. PubMed ID: 23092636
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Improving the management of patients with prostate cancer receiving long-term androgen deprivation therapy.
    Schulman C; Irani J; Aapro M
    BJU Int; 2012 Jun; 109 Suppl 6():13-21. PubMed ID: 22672121
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Androgen deprivation therapy and estrogen deficiency induced adverse effects in the treatment of prostate cancer.
    Freedland SJ; Eastham J; Shore N
    Prostate Cancer Prostatic Dis; 2009; 12(4):333-8. PubMed ID: 19901933
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Androgen deprivation therapy in prostate cancer: anticipated side-effects and their management.
    Kim HS; Freedland SJ
    Curr Opin Support Palliat Care; 2010 Sep; 4(3):147-52. PubMed ID: 20592607
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cardiovascular disease with androgen deprivation: the (forgotten) role of testosterone.
    Aragon-Ching JB
    J Clin Oncol; 2009 Dec; 27(35):e261; author reply e262. PubMed ID: 19884519
    [No Abstract]   [Full Text] [Related]  

  • 46. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer.
    Keating NL; O'Malley AJ; Smith MR
    J Clin Oncol; 2006 Sep; 24(27):4448-56. PubMed ID: 16983113
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Metabolic complications of androgen deprivation therapy and its intervention management].
    Hu YH; Wu S; Zhang M
    Zhonghua Nan Ke Xue; 2018 Mar; 24(3):277-281. PubMed ID: 30161317
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Risk of metabolic syndrome, cardiovascular disease, and diabetes in androgen deprivation therapy.
    Leahy Y
    Clin J Oncol Nurs; 2008 Oct; 12(5):771-6. PubMed ID: 18842533
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A meta-analysis of cardiovascular events in intermittent androgen-deprivation therapy versus continuous androgen-deprivation therapy for prostate cancer patients.
    Jin C; Fan Y; Meng Y; Shen C; Wang Y; Hu S; Cui C; Xu T; Yu W; Jin J
    Prostate Cancer Prostatic Dis; 2016 Dec; 19(4):333-339. PubMed ID: 27595915
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Androgen deprivation therapy for the treatment of prostate cancer: consider both benefits and risks.
    Isbarn H; Boccon-Gibod L; Carroll PR; Montorsi F; Schulman C; Smith MR; Sternberg CN; Studer UE
    Eur Urol; 2009 Jan; 55(1):62-75. PubMed ID: 18945543
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Contemporary use of hormonal therapy in prostate cancer: managing complications and addressing quality-of-life issues.
    Gomella LG
    BJU Int; 2007 Jan; 99 Suppl 1():25-9; discussion 30. PubMed ID: 17229166
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cardiovascular risk and bone loss in men undergoing androgen deprivation therapy for non-metastatic prostate cancer: implementation of standardized management guidelines.
    Cheung AS; Pattison D; Bretherton I; Hoermann R; Lim Joon D; Ho E; Jenkins T; Hamilton EJ; Bate K; Chan I; Zajac JD; Grossmann M
    Andrology; 2013 Jul; 1(4):583-9. PubMed ID: 23686896
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer.
    Saigal CS; Gore JL; Krupski TL; Hanley J; Schonlau M; Litwin MS;
    Cancer; 2007 Oct; 110(7):1493-500. PubMed ID: 17657815
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Lifestyle guidelines for managing adverse effects on bone health and body composition in men treated with androgen deprivation therapy for prostate cancer: an update.
    Owen PJ; Daly RM; Livingston PM; Fraser SF
    Prostate Cancer Prostatic Dis; 2017 Jun; 20(2):137-145. PubMed ID: 28117386
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Bone health in men receiving androgen deprivation therapy for prostate cancer.
    Eastham JA
    J Urol; 2007 Jan; 177(1):17-24. PubMed ID: 17161994
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Quantifying the evidence for the risk of metabolic syndrome and its components following androgen deprivation therapy for prostate cancer: a meta-analysis.
    Bosco C; Crawley D; Adolfsson J; Rudman S; Van Hemelrijck M
    PLoS One; 2015; 10(3):e0117344. PubMed ID: 25794005
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A randomized controlled trial of an exercise intervention targeting cardiovascular and metabolic risk factors for prostate cancer patients from the RADAR trial.
    Galvão DA; Spry N; Taaffe DR; Denham J; Joseph D; Lamb DS; Levin G; Duchesne G; Newton RU
    BMC Cancer; 2009 Dec; 9():419. PubMed ID: 19951446
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Risk of diabetes among patients receiving primary androgen deprivation therapy for clinically localized prostate cancer.
    Tsai HT; Keating NL; Van Den Eeden SK; Haque R; Cassidy-Bushrow AE; Ulcickas Yood M; Smith MR; Potosky AL
    J Urol; 2015 Jun; 193(6):1956-62. PubMed ID: 25524243
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Osteoporosis and prostate cancer: a cross-sectional study of Danish men with prostate cancer before androgen deprivation therapy.
    Poulsen MH; Frost M; Abrahamsen B; Brixen K; Walter S
    Scand J Urol; 2014 Aug; 48(4):350-5. PubMed ID: 24548220
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Androgen deprivation therapy, insulin resistance, and cardiovascular mortality: an inconvenient truth.
    Basaria S
    J Androl; 2008; 29(5):534-9. PubMed ID: 18567642
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.